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C lonidine is an imidazoline derivative with antihypertensive properties. Its 
mode of action is complex and is as yet not 
fully understood. Some datal-‘j indicate that 
an action on the central nervous system, 
predominantly at bulbar and diencephalic 
levels, causes a decreased sympathetic out- 
flow to the cardiovascular system. Other 
studies’ show a direct peripheral effect 
as well. 
Since the introduction of clonidine in 
Europe in the mid-sixties, several reports 
have been published regarding its useful- 
ness in the treatment of hypertension.8-12 
Without trying to evaluate the advantages 
or disadvantages of clonidine treatment in 
relation to those of other antihypertensive 
drugs, it is of utmost importance to be 
aware of the effects which may follow 
abrupt cessation of treatment, and which 
presumably reflect an adrenergic over- 
shoot. There have been some previous 
attempts to draw attention to the clonidine 
withdrawal crisis,13*14 but on the whole this 
is a poorly studied phenomenon. 
The present study is a description of the 
blood pressure overshoot and the typical 
symptoms that are seen when clonidine 
is stopped abruptly. Attempts have also 
been made to clarify the underlying mecha- 
nism by means of catecholamine deter- 
minations in urine and arterial blood before 
and during the crisis. Finally, suggestions 
are offered for the acute management of the 
crisis as well as a possible way to prevent 
it from occurring. 
Materials and methods 
Five patients with severe essential hyper- 
tension were studied. (See Table I for 
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Table I. Patient information 
Patient Age 




(K. W. B.*) L VHt 
Blood pressure 
Dosage of on clonidine 
clonidine (mm. Hgaverage 
(mg. daily) of 7 recordings) 
1. G. MC. 38 M Essential hypertension II yes 1.9 1 6 146/106 
2. R. E. 40 M Essential hypertension II yes 1.5 2.4 154/113 
3. P. C. 29 F Essential hypertension I no 1.2 1.6 126/93 
4. G. M. 43 M Essential hypertension II yes 1.9 1.2 170/115 
5. L. c. 53 M Essential hypertension II ll0 1.3 0.3 157/92 
*Hypertensive changes according to the Keith-Vl’agener-Barker classification. 
tLeft ventricular hypertrophy on ECG or chest x-ray. 
clinical details.) All were on chronic treat- 
ment with clonidine (2 to 4 years) and all 
had a documented previous blood pressure 
overshoot that occurred when treatment 
had been stopped temporarily for various 
reasons. 
After informed consent was obtained, the 
patients were hospitalized in the Clinical 
Research Unit. While still on their regular 
dosage of clonidine, (0.3 to 2.4 mg. daily), 
baseline studies of blood pressures were per- 
formed. Arterial and urinary catechola- 
mines were determined with the fluori- 
metric technique.‘” 
At 1O:OO P.M. on day 3, placebo was sub- 
stituted for clonidine. It was planned to 
take counteractive measures if the blood 
pressure rose excessively. During the crisis, 
urine was to be collected for catecholamine 
determinations and immediately before ad- 
ministering the alpha and beta receptor 
blockers an arterial blood sample was to be 
obtained, also for catecholamine deter- 
minations. Finally, we had decided to 
reinstitute clonidine, should the acute ad- 
ministration of propranolol and phentola- 
mine prove unsuccessful in the manage- 
ment of the crisis. If, on the other hand, the 
crisis could be overcome by these means, 
chronic oral treatment with propranolol 
and hydralazine was to be instituted, as 
the experience with this combination is 
clearly positive.16e17 
As the study proceeded, two modifica- 
tions to the above plan were introduced. 
Patient No. 3 was given oral propranolol 
and dibenzyline from the onset of with- 
drawal symptoms. 
Finally, having gained sufficient expe- 
rience with Patients 1 through 4, we at- 
tempted to alter the overshoot by pretreat- 
ment with a catecholamine depleting agent. 
Consequently, the fifth patient on the study 
received reserpine 1.0 mg. intramuscularly 
twice daily for three days before the with- 
drawal of clonidine. There is evidence in 
man that such a dosage scheme is more 
than adequate to effect a significant cat- 
echolamine depletion.ls 
Statistical comparison of blood pressure 
and catecholamine level was made by 
Student’s t test of paired observations. 
Results 
All five patients noted the change from 
clonidine to placebo within 2 to 3 hours. 
Initially they complained of restlessness 
and those who had already gone to sleep 
woke up. None of the five was able to go to 
sleep after that. Gradually an increasingly 
severe headache appeared and in combina- 
tion with this nausea and sometimes in- 
creased salivation were noted. Tremor and 
restlessness were obvious in all (see Table 
II for a complete list of symptoms). 
In Patients 1 through 4, there was a 
marked rise of blood pressure, from an 
average of 149/103 mm. Hg (average of all 
four consecutive readings during the day 
ljefore withdrawal) to an average maximum 
of 216/161 mm. Hg at an average post- 
withdrawal time of 12 hours. Compared to 
prior blood pressure readings there was a 
significant systolic blood pressure rise (67 
mm. Hg, p < 0.01) and a significant dia- 
stolic rise (5X mm. Hg, p < 0.01). At the 
time when counteractive measures were 
undertaken, the patients were markedly 
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Table II. Symptoms following clonidine withdrawal 
Patient 
No. and Insom- Vivid Head- Nausea/ Tremor Restless- Saliva- Hit- Stomach Muscle 
initials nia dreams aches anorexia ness tion cups pains pains 
1. G. MC. +++ ++ 
2. R. E. +++ 
3. P. c. 
4. G. M. + 
5. L. c. + +++ - + 
Symbols: ++f = marked; +-I- = moderate; + = mild; - = not noted. 
distressed, complaining of severe headache, 
nausea, and tremor. 
When propranolol was given (Patients 
1, 2, and 4) 0.2 mg. per kilogram of body 
weight over 2 to 4 minutes, there was an 
almost immediate relief of the restlessness 
and tremor, with little or no effect on the 
blood pressure. However, when phentola- 
mine was administered intravenously in 
5 to 10 mg. doses at successive five minute 
intervals to a total of 20 to 30 mg., there 
was a significant drop of the blood pressure 
to an average of 169/117 mm. Hg. The 
systolic drop averaged 47 mm. Hg (p < 
0.01) and the diastolic drop was 44 mm. Hg 
(p < 0.02) (Fig. 1). 
In Patient No. 3 the blood pressure peak 
was 200/135 mm. Hg (as compared to the 
average of 120/80 mm. Hg during the pre- 
ceding day). It was possible over 48 hours 
to gradually reduce the blood pressure 
toward the initial levels by oral propranolol 
40 mg. four times daily and dibenzyline 
20 mg. four times daily. 
Patient No. 5, who was pretreated with 
reserpine in order to obtain depletion of his 
catecholamine depots, had a decidedly 
milder course after the withdrawal of cloni- 
dine. Although he complained of the same 
symptoms as Patients 1 to 4, his symptoms 
were clearly of a milder degree. The blood 
pressure rise was also less marked, from 
130/95 mm. Hg to 175/120 mm. Hg at 
12 hours, and no acute treatment with 
intravenous propranolol or phentolamine 
was considered necessary. 
The average heart rate in all patients 
increased from 73 beats per minute to 
85 beats per minute (not statistically 
significant). 
The average total catecholamine levels 
in urine rose from 32 pg per 24 hours to 112 
pg per 24 hours (p < 0.02), while the arte- 
rial total catecholamines rose from 0.52 
pg per liter to 1.0 pg per liter (not statisti- 
cally significant) (see Figs. 2 and 3). 
Discussion 
Clonidine is a clearly useful antihyper- 
tensive drug, as has been pointed out in 
several studies.*-l2 Unlike most other drugs, 
however, it may cause severe withdrawal 
symptoms when it is withheld abruptly. 
Aside from the rapid and severe rise of the 
blood pressure, there is a rather constant 
array of symptoms such as insomnia, rest- 
lessness, tremor, and headache, which 
makes the crisis look very similar to that 
seen in pheochromocytoma. This picture 
plus the demonstrated increase in catechol- 
amine excretion (274 to 913 pg per 24 
hours) and the positive response to adre- 
nergic alpha and beta receptor blockers, 
seem indeed to indicate a markedly in- 
creased sympathetic discharge. However, 
the occurrence of stomach pains and rather 
pronounced nausea suggest to us that there 
is not only increased sympathetic discharge 
but increased parasympathetic activity as 
well. 
As all of our patients w-ere selected for 
the present study because of a previously 
documented blood pressure overshoot fol- 
lowing clonidine withdrawal, we are not 
able to draw conclusions regarding the 
frequency with which a withdralval crisis 
will occur. On the other hand, our findings 
seem to indicate that the phenomenon is 
reproducible. The patients experiencing 
crisis were on long-term therapy. We have 
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(lnClonldlnemlnlflol+ Over-shoot Propranolol 
(av. 7recordlnqs) over-shoot in hospital Day 4 phentolomme 
Fig. 1. Blood pressures before and during the study. Heavy lines indicate the average blood pressure. - - - 
refers to patient No. 3. - - - refers to patient No. 5 who was pretreated with reserpine. **Systolic blood pressure 
rise 67 mtn. Hg, p < 0.01. *Diastolic blood pressure rise 58 mm. Hg, p < 0.01. ttsystolic blood pressure fal 
47 mm. Hg, p < 0.01. tDiastolic blood pressure fall 44 mm. Hg, p < 0.02. 
not systematically studied the withdrawal 
phenomenon on short-term therapy (1 to 2 
months) but abortive attempts to treat 
with clonidine some hypertensive patients, 
plus the withdrawal of therapy reported in 
other studies with clonidine (see all studies 
where clonidine treatment has been fol- 
lowed by placebo therapy) suggest that the 
crisis is less dramatic after short-term ther- 
apy. Furthermore, it is to be emphasized 
that in this study relatively large doses of 
the drug were abruptly withdrawn. We 
have had less experience with tapering the 
dosage, but if the blood pressure rise can be 
counteracted, the other symptoms of crisis 
do not appear until complete withdrawal 
is attempted and they may probably be 
prevented by propranolol or reserpine pre- 
treatment. 
In regard to the acute management of 
the crisis, the logical treatment of course is 
reinstitution of clonidine. As an alternative, 
in an emergency, intravenous propranolol 
and phentolamine are useful. 
If a planned withdrawal of clonidine is 
to be undertaken, the data suggest that 
depletion of catecholamine storages, as 
with reserpine pretreatment, would be a 
logical step prior to clonidine withdrawal. 
Although our experience is limited, the 
results show that this course of action \vas 
helpful in mitigating withdrawal symptoms, 
having at least a partial effect. Thus Pa- 
tient Ko. 5, who was pretreated with 
reserpine, showed a much smaller blood 
pressure peak (175/120 mm. Hg) than at 
the previously recorded overshoot (240/150 
mm. Hg). He also seemed to suffer con- 
siderably less from the withdrau:al, al- 
though he experienced the same kind of 
symptoms (Table I). 
Finally, after the acute management of 
the crisis, it has been possible to control the 
blood pressure in Patients 1, 4, and 5 with 
oral propranolol and hydralazine at the 
same or lower blood pressure levels as dur- 
ing clonidine treatment. 
Conclusions 
The following conclusions seem war- 
ranted : 
1. Acute withdrawal of clonidine may 
cause a severe and potentially fatal blood 
pressure overshoot. 
2. The accompanying symptoms as well 
as the increased catecholamine excretion 
and the response to adrenergic blockers 
indicate an increased sympathetic dis- 
charge. This is possibly accompanied by an 
increased parasympathetic activity. 
3. In the acute crisis, combined alpha 
and beta receptor blockade with phentola- 
mine and propranolol seems useful. 
4. Depletion of catecholamine stores, 
e.g., with reserpine prior to withdrawal of 
clonidine, may reduce the withdrawal 
Volume 85 





Fig. 2. Per cent increase of total urinary catechola- 
mines. - - - refers to patient No. 5, who was 
pretreated with reserpine. 
symptoms and the blood pressure rise. 
In view of our findings, it is obvious that 
the patients need to be informed about the 
possible dangers of suddenly stopping cloni- 
dine treatment. They should be warned 
always to have an alternate supply for 
emergencies should they be on vacations or 
in places where the drug may not be easily 
available. Withdrawal of clonidine prior to 
surgery is not recommended since a crisis 
may appear about 12 hours later and inter- 
fere seriouslv with postoperative care. If all 
oral medication must be withdrawn, clonil 
dine should be supplied intravenously or by 
gastric tube or plans should be made to 
maintain the patient on propranolol-phen- 
tolamine during the postoperative interval. 
Finally, this study has shown that if 
patients on long-term clonidine therapy are 
to be considered for conversion to other 
forms of antihypertensive management, the 
transition must be managed carefullv using 
reserpine, propranolol, or other antihyper- 
tensive agents with considerable attention 
to the detailed day-to-day blood pressure. 
Summary 
In five patients with severe essential 
hvpertension, placebo was substituted after 
24 to 48 months of treatment with clonidine 
and a diuretic. In the present study, four of 
the patients developed a marked blood 





Fiq. 3. Per cent increase of total arterial catechola- 
mines. - - - refers to patient No. 5, who was 
pretreated with reserpine. 
dine which was rapidly reversed by intra- 
venous administration of propranolol 0.2 
mg. per kilogram of body weight and phen- 
tolamine 20 to 30 mg. The fifth patient was 
pretreated with reserpine 2.0 mg. intra- 
muscularly for three days prior to with- 
drawal of clonidine, and the blood pressure 
rise which he experienced was far less im- 
pressive. All patients experienced similar 
“withdrawal” symptoms, consisting of 
headaches, insomnia, restlessness, tremor, 
and nausea. 
Catecholamines were determined in arte- 
rial blood and urine, before and during the 
overshoot. They revealed a marked in- 
crease, particularly in the urine samples, 
consistent with the appearance of a hyper- 
adrenergic state. 
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